

# Jeanne E Poole

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6454248/publications.pdf>

Version: 2024-02-01

74  
papers

12,419  
citations

136940

32  
h-index

95259

68  
g-index

74  
all docs

74  
docs citations

74  
times ranked

8209  
citing authors

#	ARTICLE	IF	CITATIONS
1	Amiodarone or an Implantable Cardioverter-Defibrillator for Congestive Heart Failure. <i>New England Journal of Medicine</i> , 2005, 352, 225-237.	27.0	5,972
2	Prognostic Importance of Defibrillator Shocks in Patients with Heart Failure. <i>New England Journal of Medicine</i> , 2008, 359, 1009-1017.	27.0	1,282
3	Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1261.	7.4	953
4	Complication Rates Associated With Pacemaker or Implantable Cardioverter-Defibrillator Generator Replacements and Upgrade Procedures. <i>Circulation</i> , 2010, 122, 1553-1561.	1.6	658
5	The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. <i>Lancet, The</i> , 2021, 397, 2385-2438.	13.7	530
6	Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1275.	7.4	388
7	Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure. <i>Circulation</i> , 2021, 143, 1377-1390.	1.6	223
8	European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio. <i>Europace</i> , 2020, 22, 515-549.	1.7	216
9	Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure. <i>Circulation</i> , 2009, 120, 2170-2176.	1.6	213
10	Low-Energy Impedance-Compensating Biphasic Waveforms Terminate Ventricular Fibrillation at High Rates in Victims of Out-of-Hospital Cardiac Arrest. <i>Journal of Cardiovascular Electrophysiology</i> , 1997, 8, 1373-1385.	1.7	123
11	European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio. <i>European Heart Journal</i> , 2020, 41, 2012-2032.	2.2	120
12	Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3105-3118.	2.8	119
13	European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 57, e1-e31.	1.4	111
14	Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design. <i>American Heart Journal</i> , 2018, 199, 192-199.	2.7	107
15	Truncated Biphasic Pulses for Transthoracic Defibrillation. <i>Circulation</i> , 1995, 91, 1768-1774.	1.6	79
16	Primary Prevention with Defibrillator Therapy in Women: Results from the Sudden Cardiac Death in Heart Failure Trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2008, 19, 720-724.	1.7	77
17	QRS Duration or QRS Morphology. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1104-1117.	2.8	77
18	Rapid-Rate Nonsustained Ventricular Tachycardia Found on Implantable Cardioverter-Defibrillator Interrogation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2161-2168.	2.8	60

#	ARTICLE	IF	CITATIONS
19	Prognostic Value of Late Gadolinium Enhancement for the Prediction of Cardiovascular Outcomes in Dilated Cardiomyopathy. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e010105.	2.6	60
20	Increasing Participation of Women in Cardiovascular Trials. <i>Journal of the American College of Cardiology</i> , 2021, 78, 737-751.	2.8	60
21	Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 767.	6.1	59
22	Use of Guideline-Directed Medications for Heart Failure Before Cardioverter-Defibrillator Implantation. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1062-1069.	2.8	57
23	Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. <i>EClinicalMedicine</i> , 2021, 33, 100773.	7.1	55
24	Worldwide Randomized Antibiotic Envelope Infection Prevention Trial (WRAP-IT). <i>American Heart Journal</i> , 2016, 180, 12-21.	2.7	53
25	Clinical practice and implementation of guidelines for the prevention, diagnosis and management of cardiac implantable electronic device infections: results of a worldwide survey under the auspices of the European Heart Rhythm Association. <i>Europace</i> , 2019, 21, 1270-1279.	1.7	49
26	Ventricular Arrhythmias Detected After Transvenous Defibrillator Implantation in Patients With a Clinical History of Only Ventricular Fibrillation. <i>Circulation</i> , 1995, 91, 1996-2001.	1.6	49
27	Association Between Sex and Treatment Outcomes of Atrial Fibrillation Ablation Versus Drug Therapy. <i>Circulation</i> , 2021, 143, 661-672.	1.6	47
28	Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results From the CABANA Trial. <i>Circulation</i> , 2022, 145, 796-804.	1.6	44
29	Defibrillation for Ventricular Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1496-1509.	2.8	43
30	Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the ASCD-HeFT. <i>Journal of the American College of Cardiology</i> , 2020, 76, 405-415.	2.8	43
31	Who Should Receive the Subcutaneous Implanted Defibrillator?. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 1236-1245.	4.8	40
32	Unexpected Deviation in Circadian Variation of Ventricular Arrhythmias. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2702-2708.	2.8	34
33	Serial Defibrillation Threshold Measures in Man: A Prospective Controlled Study. <i>Journal of Cardiovascular Electrophysiology</i> , 1995, 6, 19-25.	1.7	32
34	Multicenter Automatic Defibrillator Implantation Trial "Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. <i>American Heart Journal</i> , 2017, 189, 158-166.	2.7	31
35	A Prospective Randomized Comparison in Humans of Biphasic Waveform 60-1/4F and 120-1/4F Capacitance Pulses Using a Unipolar Defibrillation System. <i>Circulation</i> , 1995, 91, 91-95.	1.6	31
36	Prospective Randomized Comparison of Biphasic Waveform Tilt Using a Unipolar Defibrillation System. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1995, 18, 1369-1373.	1.2	30

#	ARTICLE	IF	CITATIONS
37	Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities. Journal of the American College of Cardiology, 2021, 78, 126-138.	2.8	28
38	Malignant Sustained Ventricular Tachyarrhythmias in Women:.. Journal of Cardiovascular Electrophysiology, 1997, 8, 2-10.	1.7	27
39	Management of Arrhythmias After Heart Transplant. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e007954.	4.8	19
40	Use of the 6-Min Walk Distance to Identify Variations in Treatment Benefits From Implantable Cardioverter-Defibrillator and Amiodarone. Journal of the American College of Cardiology, 2014, 63, 2560-2568.	2.8	18
41	Comparison of 2 ambulatory patch ECG monitors: The benefit of the P-wave and signal clarity. American Heart Journal, 2018, 203, 109-117.	2.7	18
42	Arrhythmias in Female Patients: Incidence, Presentation and Management. Circulation Research, 2022, 130, 474-495.	4.5	17
43	Prospective Evaluation of the Effect of Biphasic Waveform Defibrillation on Ventricular Pacing Thresholds. Journal of Cardiovascular Electrophysiology, 1997, 8, 485-485.	1.7	15
44	A Prospective Randomized Comparison in Humans of 90-F and 120-F Biphasic Pulse Defibrillation Using a Unipolar Defibrillation System. Journal of Cardiovascular Electrophysiology, 1995, 6, 1097-1100.	1.7	14
45	Automated External Defibrillator Users: Untrained Bystanders: Can They Publicly Use a Model? Prehospital Emergency Care, 2004, 8, 284-291.	1.8	13
46	QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019. Heart Rhythm O2, 2020, 1, 167-172.	1.7	13
47	Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates. JACC: Clinical Electrophysiology, 2018, 4, 1089-1102.	3.2	12
48	Rationale and design of the Home Automatic External Defibrillator Trial (HAT). American Heart Journal, 2008, 155, 445-454.	2.7	11
49	Subcutaneous ICD screening with the Boston Scientific ZOOM programmer versus a 12-lead ECG machine. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 511-516.	1.2	10
50	Treatment-Related Changes in Left Atrial Structure in Atrial Fibrillation: Findings From the CABANA Imaging Substudy. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008540.	4.8	9
51	Influence of atrial fibrillation type on outcomes of ablation vs. drug therapy: results from CABANA. Europace, 2022, 24, 1430-1440.	1.7	9
52	A Prospective Randomized Comparison of Defibrillation Efficacy of Truncated Pulses and Damped Sine Wave Pulses in Humans. Journal of Cardiovascular Electrophysiology, 1994, 5, 725-730.	1.7	8
53	Defibrillator Therapy in Chronic Kidney Disease. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 774-776.	4.8	8
54	Subcutaneous Implantable Cardioverter-Defibrillator Finding a Place in Sudden Cardiac Death Prevention. Journal of the American College of Cardiology, 2017, 70, 842-844.	2.8	6

#	ARTICLE	IF	CITATIONS
55	A wearable cardioverter defibrillator with a low false alarm rate. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 831-842.	1.7	6
56	Clinical performance of implantable cardioverter-defibrillator lead monitoring diagnostics. <i>Heart Rhythm</i> , 2022, 19, 363-371.	0.7	5
57	Identifying risk of adverse outcomes in COVID-19 patients via artificial intelligenceâ€‘powered analysis of 12-lead intake electrocardiogram. <i>Cardiovascular Digital Health Journal</i> , 2022, 3, 62-74.	1.3	5
58	Understanding Implantable Cardioverter-Defibrillator Shocks and Mortality. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1680-1682.	2.8	4
59	Novel ICD therapy begets novel ICD detection: First look at the performance of the subcutaneous ICD discrimination algorithm. <i>Heart Rhythm</i> , 2014, 11, 1359-1360.	0.7	4
60	New indications for implantable defibrillator therapy. <i>Current Cardiology Reports</i> , 2006, 8, 330-335.	2.9	3
61	The Right Response to Nonresponse to Cardiac Resynchronization Therapy. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2604-2606.	2.8	3
62	Secondary Prevention. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 29-32.	3.2	2
63	Factors and outcomes associated with improved left ventricular systolic function in patients with cardiomyopathy. <i>Cardiology Journal</i> , 2022, 29, 978-984.	1.2	2
64	Improved Survival Using a Quadripolar Cardiac Resynchronization Lead. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 434-437.	3.2	1
65	BRUISE CONTROL INFECTION Study. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1309-1311.	2.8	1
66	What We Know, What We Think We Know, and What We Do Not Know at All. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e006245.	4.8	1
67	Outcomes for Patients with Anterior Myocardial Infarction and Prior Cardiac Arrest in the Home Automated External Defibrillator Trial (HAT). <i>Resuscitation</i> , 2021, 168, 75-83.	3.0	1
68	AnaLysis of Both sex and device specific factoRs on outcomes in pAtients with non-ischemic cardiomyopathy (BIO-LIBRA): Design and clinical protocol. <i>Heart Rhythm O2</i> , 2020, 1, 376-384.	1.7	1
69	Reply. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2028-2029.	2.8	0
70	Will the Real Left Bundle Branch Block Please Stand Up?â€‘. <i>Journal of the American College of Cardiology</i> , 2015, 66, 642-644.	2.8	0
71	Outcomes That Matter. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 340-342.	3.2	0
72	Cardiac Resynchronization Therapy in Nonischemic Cardiomyopathy. <i>JACC: Heart Failure</i> , 2021, 9, 450-452.	4.1	0

#	ARTICLE	IF	CITATIONS
73	Global Voices. Heart Rhythm O2, 2022, 3, 119.	1.7	0
74	Arrhythmias in heart failureâ€”Where the past meets the future. Heart Rhythm O2, 2021, 2, 669-670.	1.7	0